The results of this metanalysis indicate that the addition of at least one year of trastuzumab to anthracycline and taxane-containing chemotherapy provides substantial benefit for women with HER2-positive breast cancer, both in terms of disease recurrence and survival. The gene discussed is ERBB2; the disease is breast carcinoma.